<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00467285</url>
  </required_header>
  <id_info>
    <org_study_id>ENDB-019-06S</org_study_id>
    <nct_id>NCT00467285</nct_id>
  </id_info>
  <brief_title>Effect of Diabetic Medications on Bone Metabolism</brief_title>
  <official_title>Effect of Thiazolidinediones on Skeletal Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects with diabetes and pre-diabetes are said to have increased bone loss when compared to
      the general population. Pioglitazone a thiazolidinedione, is a Food and Drug Administration
      (FDA) approved oral anti-diabetic agent for the treatment of type 2 diabetes. Though there
      are many benefits for using thiazolidinediones in the treatment of type 2 diabetes, there is
      data that indicates that rosiglitazone therapy results in a significant decrease in total
      body bone mineral density in mice. Whether it is true in humans is not clear. If the animal
      data can be extrapolated to humans, thiazolidinediones may pose a significant risk of adverse
      effects on bone. This study hypothesizes that treatment with the thiazolidinedione
      pioglitazone may result in significant reduction in bone mineral density. The aims of this
      are: 1. to evaluate the effect of pioglitazone on skeletal health; 2. to measure the bone
      mineral density (BMD) of the spine and hip, as well as bone turnover markers, at different
      times of persons taking thiazolidinediones and others not taking them; 3. to determine the
      change in BMD and bone turnover markers within different groups at different times; and 4. to
      compare these changes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence rate of diabetes among veterans is 16% in general and 27% at out medical
      center compared to 6.3% among United States population. Subjects with diabetes and
      prediabetes said to have increased bone loss compared to the general population.
      Pioglitazone, a thiazolidinedione, is a Food and Drug Administration (FDA) approved oral
      anti-diabetic agent for the treatment of type 2 diabetes. Most of the pleiotropic effects of
      teh thiazolidinediones are beneficial in atherosclerosis and cancer, in addition to improving
      insulin resistance. Data from studies in mice show that rosiglitazone and pioglitazone
      therapy results in a significant decrease in total body bone mineral density was observed.
      Whether it is true in humans is not clear. There are no prospective studies to date. Subjects
      with diabetes are already at an increased risk for femoral fractures. If the animal data can
      be can be extrapolated to humans, thiazolidinedione pioglitazone may result in significant
      risk of adverse skeletal effects. This study hypothesizes that treatment with the
      thiazolidinedione pioglitazone may result in a significant reduction in bone mineral density.
      The aims of the study include: 1. To prospectively evaluate the effect of pioglitazone on
      skeletal health, we will study 140 subjects with diabetes receiving pioglitazone as part of
      their diabetes management and compare them with 140 diabetic controls (matched for age, sex,
      body mass index (BMI), smoking and alcohol history), not treated with pioglitazone. 2. To
      measure the bone mineral density by DXA at AP spine and hip, as well as bone turnover
      markers-procollagen type 1C-terminal propeptide (P1CP), and procollagen type 1N-terminal
      propeptide (P1NP), bone specific alkaline phosphatase, osteocalcin, plasma C-telopeptide
      (CTx) and N-telopeptide (NTx) at baseline, six and 12 months of follow-up. 3. To determine
      the change in BMD and bone turnover markers within each group from baseline to follow-up at
      six and 12 months. 4. To compare the changes in the BMD and bone turnover markers between
      groups at baseline and follow-up at six and 12 months.

      Subjects: Prospectively study 140 subjects with type 2 diabetes and on pioglitazone, age, and
      sex matched controls.

      Sample Size: The sample size is based on the primary objective of comparing the levels bone
      turnover markers and bone mineral density changes in diabetes with or without avandia.

      Number of visits: 140 subjects with diabetes and on pioglitazone and 140 subjects with
      diabetes not on pioglitazone

        1. Subjects will be studies at three visits.

        2. The procedures to be done include assessment of bone mineral density measurement by dual
           X-ray absorptiometry (DXA), measurement of bone turnover markers like serum osteocalcin
           and urinary N-telopeptide after the informed consent. About 15ml (one tablespoonful) of
           blood will be drawn at each visit for the study.

        3. All the baseline measurements will be repeated at 6 months and at one year.

        4. Statistical analysis of the data will be done to compare the changes in bone turnover
           markers and bone mineral density between the two groups.

      Site of the study: Overton Brooks VAMC Diabetics clinic and Primary care clinics.

      If our hypothesis is proven correct, subjects with diabetes requiring thiazolidinediones
      should have bone turnover markers and BMD measurement at baseline and have serial follow up.
      Identification of subjects at high risk will allow health care providers to initiate
      necessary protective measures to protect the bone to decrease the fracture risk.

      Potential Impact on Veterans Health Care: Identification of subjects at high risk will allow
      health care providers to initiate necessary preventive measures to protect the bone and
      decrease the risk of fractures, or avoid the use of TZDs altogether in select patients. Since
      the prevalence of diabetes is very high among veterans, evaluation of a possible risk of
      skeletal health with the use of pioglitazone is highly relevant to VA health care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in BMD at Femoral Neck</measure>
    <time_frame>6 months</time_frame>
    <description>% changes in BMD ( BMD at Lumbar spine, femoral neck and 0.33 radius) and bone turn over markers in subjects with diabetes on pioglitazone compared to those who are not on Pioglitazone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in BMD Total Hip</measure>
    <time_frame>6 months</time_frame>
    <description>% change at 6 month follow up compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in BMD AP Spine</measure>
    <time_frame>6 months</time_frame>
    <description>% change in BMD at 6 month follow up compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in BMD 0.33 Radius</measure>
    <time_frame>6 months</time_frame>
    <description>% change in BMD at 6 month follow up compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CTx</measure>
    <time_frame>6 months</time_frame>
    <description>% Change in bone turnover markers at 6 month follow up compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteocalcin</measure>
    <time_frame>6 months</time_frame>
    <description>% change at 6 month follow up compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CTx at Follow up</measure>
    <time_frame>6 months</time_frame>
    <description>% change in the levels of CTx at 6 months follow up compared to baseline</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">96</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>140 subjects with type 2 diabetes on pioglitazone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>140 subjects with type 2 diabetes not on pioglitazone.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine and serum samples collected for the study will be spin and stored at -70 degree C and
      assays run intermittently
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        subjects with type 2 diabetes and less than 55 years with or without pioglitazone as part
        of their therapy for diabetes
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 30-55 years

          -  Gender: men and women

          -  Ethnicity: all ethnic groups

          -  140 subjects with diabetes and no pioglitazone (recently started i.e. less than 3
             months as well as those who have just initiated pioglitazone treatment)

          -  140 control subjects (subjects with diabetes and not on pioglitazone) will be included

          -  The control subjects will be chosen to match age, sex, ethnicity and comparable
             smoking and alcohol history

          -  To avoid confusion factor of vitamin D and calcium intake, all the subjects will be
             given vitamin D and calcium supplements (USDA recommended doses)

        Exclusion Criteria:

          -  Patients who are unable or unwilling yo give informed consent

          -  Immobilized or bed bound subject

          -  Subjects wil known diseases associated with disordered bone metabolism such as chronic
             renal insufficiency, chronic steroid use, primary hyperparathyroidism, untreated
             subclinical or clinical hyperthyroidism and Paget's disease. To identify subjects with
             decreased Glomerular filtration rate (GFR) even if creatinine is normal will be
             excluded (at the proposed study site, routine bm includes calculated GFR from the
             chemistry lab)

          -  Patients on medications that will alter bone metabolism will be excluded. They are
             glucocorticoids, gonadal hormones (testosterone in men and estrogen in women).

          -  Subjects with known history of chronic pancreatitis, pancreatectomy or malabsorption
             syndromes to avoid confounding factors known to affect vitamin D metabolism and
             indirectly bone mineral metabolism.

          -  Female patients with perimenopause or menopause: history of hypogonadism (History of
             ovariectomy or postmenopausal women) to avoid bone turn over changes secondary to
             hypogonadism. Perimenopausal women identifies by screening FSH and LH and excluding
             women with elevated FSH be excluded to avoid perimenopausal effect on bone turnover
             (women over 35 will still have a screening gonadal hormonal evaluation).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Subhashini Yaturu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albany VA Medical Center Samuel S. Stratton, Albany, NY</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://dx.doi.org/10.4236/jdm.2012.21006</url>
    <description>journal web site with link to the article</description>
  </link>
  <results_reference>
    <citation>Yaturu S, Dier U, Cui H, Mousa SA. Aspirin resistance in young men with Type 2 diabetes. Journal of diabetes mellitus. 2014 Jan 1; 4(1):72-6.</citation>
  </results_reference>
  <results_reference>
    <citation>Yaturu S, Davis J, Shi R. Decreased bone mineral density in young male veterans on Pioglitazone*. Journal of diabetes mellitus. 2012 Jan 1; 2(1):35-9.</citation>
  </results_reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2007</study_first_submitted>
  <study_first_submitted_qc>April 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2007</study_first_posted>
  <results_first_submitted>December 2, 2014</results_first_submitted>
  <results_first_submitted_qc>January 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 14, 2015</results_first_posted>
  <last_update_submitted>January 13, 2015</last_update_submitted>
  <last_update_submitted_qc>January 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone Density</keyword>
  <keyword>C-telopeptide</keyword>
  <keyword>Dual-Energy X-Ray Absorptiometry</keyword>
  <keyword>N-telopeptide</keyword>
  <keyword>Osteocalcin</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Thiazolidinediones</keyword>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2,4-thiazolidinedione</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Endo-Research clinic</recruitment_details>
      <pre_assignment_details>Young male veterans with type 2 diabetes with creatinine less than 1.4, aged less than 55 years</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>32 subjects with type 2 diabetes on pioglitazone.</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>64 subjects with type 2 diabetes not on pioglitazone, less than 55 years old.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pioglitazone</title>
          <description>32 subjects with type 2 diabetes on pioglitazone.</description>
        </group>
        <group group_id="B2">
          <title>No Pioglitazone</title>
          <description>64 subjects with type 2 diabetes not on pioglitazone, less than 55 years old.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="64"/>
            <count group_id="B3" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="2"/>
                    <measurement group_id="B2" value="49" spread="2"/>
                    <measurement group_id="B3" value="49" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ctx</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" spread="2"/>
                    <measurement group_id="B2" value="19" spread="3"/>
                    <measurement group_id="B3" value="22" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in BMD at Femoral Neck</title>
        <description>% changes in BMD ( BMD at Lumbar spine, femoral neck and 0.33 radius) and bone turn over markers in subjects with diabetes on pioglitazone compared to those who are not on Pioglitazone</description>
        <time_frame>6 months</time_frame>
        <population>28 subjects on pioglitazone and 64 subjects not on pioglitazone</population>
        <group_list>
          <group group_id="O1">
            <title>Piogliazone</title>
            <description>32 Subjects with type 2 diabetes on Pioglitazone</description>
          </group>
          <group group_id="O2">
            <title>No Pioglitazone</title>
            <description>64 subjects with type 2 diabetes not on pioglitazone</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in BMD at Femoral Neck</title>
          <description>% changes in BMD ( BMD at Lumbar spine, femoral neck and 0.33 radius) and bone turn over markers in subjects with diabetes on pioglitazone compared to those who are not on Pioglitazone</description>
          <population>28 subjects on pioglitazone and 64 subjects not on pioglitazone</population>
          <units>percentage of change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="0.25"/>
                    <measurement group_id="O2" value="0.25" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>comparison of changes in BMD at 6months compared to baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CTx</title>
        <description>% Change in bone turnover markers at 6 month follow up compared to baseline</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Characteristics: Group 1</title>
            <description>Mean age of 49 with mean BMI 0f 33.6 ± 5; HbA1C of 7.54</description>
          </group>
          <group group_id="O2">
            <title>Baseline Characteristics: Group 2</title>
            <description>Mean age of 49 with mean BMI 0f 35.2 ± 5; HbA1C of 7.45</description>
          </group>
        </group_list>
        <measure>
          <title>CTx</title>
          <description>% Change in bone turnover markers at 6 month follow up compared to baseline</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="2.1"/>
                    <measurement group_id="O2" value="4.8" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Osteocalcin</title>
        <description>% change at 6 month follow up compared to baseline</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Piogliazone</title>
            <description>32 Subjects with type 2 diabetes on Pioglitazone</description>
          </group>
          <group group_id="O2">
            <title>No Pioglitazone</title>
            <description>64 subjects with type 2 diabetes not on pioglitazone</description>
          </group>
        </group_list>
        <measure>
          <title>Osteocalcin</title>
          <description>% change at 6 month follow up compared to baseline</description>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.49" spread="2.5"/>
                    <measurement group_id="O2" value="-12.44" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in BMD Total Hip</title>
        <description>% change at 6 month follow up compared to baseline</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Piogliazone</title>
            <description>32 Subjects with type 2 diabetes on Pioglitazone</description>
          </group>
          <group group_id="O2">
            <title>No Pioglitazone</title>
            <description>64 subjects with type 2 diabetes not on pioglitazone</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in BMD Total Hip</title>
          <description>% change at 6 month follow up compared to baseline</description>
          <units>% change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="0.24"/>
                    <measurement group_id="O2" value="-0.2" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in CTx at Follow up</title>
        <description>% change in the levels of CTx at 6 months follow up compared to baseline</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Piogliazone</title>
            <description>32 Subjects with type 2 diabetes on Pioglitazone</description>
          </group>
          <group group_id="O2">
            <title>No Pioglitazone</title>
            <description>64 subjects with type 2 diabetes not on pioglitazone</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in CTx at Follow up</title>
          <description>% change in the levels of CTx at 6 months follow up compared to baseline</description>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" spread="2"/>
                    <measurement group_id="O2" value="19" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in BMD AP Spine</title>
        <description>% change in BMD at 6 month follow up compared to baseline</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Piogliazone</title>
            <description>32 Subjects with type 2 diabetes on Pioglitazone</description>
          </group>
          <group group_id="O2">
            <title>No Pioglitazone</title>
            <description>64 subjects with type 2 diabetes not on pioglitazone</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in BMD AP Spine</title>
          <description>% change in BMD at 6 month follow up compared to baseline</description>
          <units>% change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.04"/>
                    <measurement group_id="O2" value="0.89" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in BMD 0.33 Radius</title>
        <description>% change in BMD at 6 month follow up compared to baseline</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Piogliazone</title>
            <description>32 Subjects with type 2 diabetes on Pioglitazone</description>
          </group>
          <group group_id="O2">
            <title>No Pioglitazone</title>
            <description>64 subjects with type 2 diabetes not on pioglitazone</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in BMD 0.33 Radius</title>
          <description>% change in BMD at 6 month follow up compared to baseline</description>
          <units>% change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="0.22"/>
                    <measurement group_id="O2" value="-0.21" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>adverse events not collected</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pioglitazone</title>
          <description>Subjects on pioglitazone</description>
        </group>
        <group group_id="E2">
          <title>No Pioglitazone</title>
          <description>Subjects not on pioglitazone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Subhashini Yaturu</name_or_title>
      <organization>Samuel Stratton VAMC</organization>
      <phone>518-626-5642</phone>
      <email>Subhashini.Yaturu@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

